Journal Scans
Long-Term Follow-Up of Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia After Stem Cell Mobilization Under Imatinib
8-Year Follow-Up of Imatinib-Treated Ph+ CML in CCyR After AutoSCT
TD Kim, M Schwarz, KA Kreuzer, J Kaeda, K Movassaghi, P Grille, PT Daniel, B Dörken, P le Coutre
Yes
20101106
2010 Dec 6
Leukemia and Lymphoma
Long-Term Follow-Up of Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia After Stem Cell Mobilization Under Imatinib
Leukemia and Lymphoma. 2010 Dec 6;[Epub Ahead of Print], TD Kim, M Schwarz, KA Kreuzer, J Kaeda, K Movassaghi, P Grille, PT Daniel, B Dörken, P le Coutre
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Results of the phase III randomized IRIS trial (International Randomized Interferon vs. STI-571) led to the adoption of the tyrosine kinase inhibitor (TKI) imatinib mesylate (IM) as standard first-line therapy for patients with chronic myeloid leukemia (CML). However, more than 30% of newly diagnosed patients with chronic-phase (CP) disease will discontinue IM within 6 years, largely because of resistant disease. Autologous stem cell transplant (ASCT) can induce long-term remission in a subset of...
